Skip to content

Author

J. McMurray

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial

Prognostically important comorbidities such as diabetes, hypertension, and coronary disease are uncommon in patients with heart failure with reduced ejection fraction (HFrEF) secondary to chronic Chagas cardiomyopathy, yet these patients have worse outcomes, including worse survival, compared with other HF etiolo...

L. Echeverria, C. Demacq, E. Bocchi et al. · 0 citations
Open access Oct 2026

Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)

The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces left ventricular (LV) volumes in heart failure with reduced ejection fraction (HFrEF). Whether this effect is additive to optimal background guideline-recommended therapy is unknown. To evaluate the effects of empagliflozin according to key...

M. Lee, C. Berry, R. Campbell et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.